Growth differentiation factor-15 and prognosis in acute respiratory distress syndrome: a retrospective cohort study

We sought to determine whether higher levels of the novel biomarker growth differentiation factor-15 (GDF-15) are associated with poor outcomes and the presence of pulmonary vascular dysfunction (PVD) in patients with acute respiratory distress syndrome (ARDS). We conducted a retrospective cohort st...

Full description

Saved in:
Bibliographic Details
Published in:Critical care (London, England) England), 2013-05, Vol.17 (3), p.R92-R92, Article R92
Main Authors: Clark, Brendan J, Bull, Todd M, Benson, Alexander B, Stream, Amanda R, Macht, Madison, Gaydos, Jeanette, Meadows, Christina, Burnham, Ellen L, Moss, Marc
Format: Article
Language:English
Subjects:
Acute respiratory distress syndrome
Adult
Biomarkers - blood
Catheterization, Swan-Ganz
Female
Fluid Therapy
Genetic aspects
Growth Differentiation Factor 15 - blood
Humans
Male
Middle Aged
Mortality
Myostatin
Physiological aspects
Prognosis
Pulmonary Artery - physiopathology
Respiratory Distress Syndrome, Adult - blood
Respiratory Distress Syndrome, Adult - mortality
Respiratory Distress Syndrome, Adult - physiopathology
Respiratory Distress Syndrome, Adult - therapy
Retrospective Studies
United Kingdom
United States
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:We sought to determine whether higher levels of the novel biomarker growth differentiation factor-15 (GDF-15) are associated with poor outcomes and the presence of pulmonary vascular dysfunction (PVD) in patients with acute respiratory distress syndrome (ARDS). We conducted a retrospective cohort study in patients enrolled in the Acute Respiratory Distress Syndrome Network Fluid and Catheter Treatment (FACT) Trial. Patients enrolled in the FACT Trial who received a pulmonary artery catheter (PAC), had plasma available from the same study day and sufficient hemodynamic data to determine the presence of PVD were included. Logistic regression was used to determine the association between GDF-15 level and 60-day mortality. Of the 513 patients enrolled in the FACT Trial assigned to receive a PAC, 400 were included in this analysis. Mortality at 60 days was significantly higher in patients whose GDF-15 levels were in the third (28%) or fourth (49%) quartile when compared to patients with GDF-15 levels in the first quartile (12%) (P
ISSN:1364-8535
1466-609X
1364-8535
DOI:10.1186/cc12737